

UNITED STATE EPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

جع

APPLICATION NO. FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/928,074 09/11/97	FISH	.F 07256-024001 EXAMINER
FREDERICK P FISH SUITE 1400 4225 EXECUTIVE SQUARE LA JOLLA CA 92037	HM22/0113	HAYES, R ART UNIT PAPER NUMBER 1645 DATE MAILED: 01/13/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

UNITED CATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER FILING DATE	FIRST NAMED	APPLICANT ATTORNEY DOCKET NO.
08/928,074	1	EXAMINER ART UNIT PAPER NUMBER 10 DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With 1.821 through 1.825 for Patent Applications Containing Nucleotide Sequence And/Or Amino Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. It should also be noted that 37 CFR 1.821 (a)(2)(c-d) Acid Sequence Disclosures. It should also be noted that 37 CFR 1.821 (a)(2)(c-d) states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each sequence disclosed must appear separately in the "Sequence listing" states that each seq

Any inquiry concerning this communication should be directed to Examiner Robert C. Hayes, Art Unit 1645, whose telephone number is 703-305-3132.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is extend to return a copy of the attached Notice to Comply with the response.

Robert C. Hayes, Ph.D. January 11, 1999

ANTHONY C. CAPUTA PRIMARY EXAMINER NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

ng reason(s):	
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.823. Application 1. This ap	
18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence" 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence" 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence"	
2. This application does not contain, as a separate publishing as required by 37 C.F.R. 1.821(c). Listing as required by 37 C.F.R. 1.821(c).	
Listing" as required by 57 G. H. Listing as required by 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822	
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute and/or unreadable form must be submitted as required by 37 C.F.R. 1.825(d).	
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry	
into the specification.	
into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For questions regarding compliance to these requirements, please contact:	
For CRF Submission Help, Call (1994)	
Patentin Software Program Support (* 703-287-0200	
Technical Assistance703-306-2600 To Purchase Patentin Software703-306-2600	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE